A Phase 3 interventional study of Tedizolid Phosphate (Sivextro, BAY1192631) and Linezolid in Skin Diseases, Infectious, sponsored by Bayer. Completed at 46 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-04.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
45 studies on the registry are indexed under Skin Diseases, Infectious; 2 are open to participants now.
This study's enrollment of 125 is below the median of 161 across 37 interventional studies indexed under Skin Diseases, Infectious.
Browse Skin Diseases, Infectious studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
Drug: Tedizolid Phosphate (Sivextro, BAY1192631)
Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
Drug: Linezolid
BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Clinical Response at Test of Cure (TOC)
Clinical response was evaluated by the masked investigator as clinical cure, clinical failure and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.
Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
Microbiological Response at Test of Cure (TOC)
Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.
Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
Clinical Response at End of Treatment Visit (EOT)
Clinical response was evaluated by the masked investigator as effective, ineffective and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.
Time frame: 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia from the study drug administration
Microbiological Response at End of Treatment (EOT)
Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.
Time frame: 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia from the study drug administration
Change of the Lesion Size From the Screening Visit by Visit (Only Skin and Soft Tissue Infection [SSTI])
Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest.
Time frame: Multiple time points up to 7-14 days after the end of treatment
Reduction Ratio of the Lesion Size From the Screening Visit to Day 3 to Day 4 Visit (Only Skin and Soft Tissue Infection [SSTI])
Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest. Reduction ratio (%) = 100 \* (the post baseline value - baseline value) / baseline value. Negative values represent reduction of lesion size compared to baseline.
Time frame: Baseline and Day 3/4, Day 5/13, EOT, TOC
The study was conducted in 46 study centers in Japan from 23 November 2013 (first subject, first visit) to 28 October 2016 (last subject, last visit).
| Milestone | Tedizolid Phosphate (Sivextro, BAY1192631) | Linezolid |
|---|---|---|
| Started | 84 | 41 |
| Participants received treatment | 83 | 41 |
| Completed | 72 | 38 |
| Not completed | 12 | 3 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Switching to other therapy | 2 | 0 |
| Withdrew: Protocol driven decision point | 1 | 0 |
| Withdrew: Logistical difficulties | 1 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
Clinical response was evaluated by the masked investigator as clinical cure, clinical failure and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.
| Percentage of participants | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia |
|---|---|---|---|---|
| Clinical cure | 86.2 (75.7 to 99.1) | 80.0 | — | 0.0 |
| Clinical failure | 6.9 | 10.0 | — | 0.0 |
| Indeterminate | 6.9 | 10.0 | — | 100.0 |
Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.
| Percentage of participants | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia |
|---|---|---|---|---|
| Eradication | 93.1 | 90.0 | — | 100.0 |
| Persistence | 3.4 | 0.0 | — | 0.0 |
| Elimination(indeterminate) | 0.0 | 0.0 | — | 0.0 |
| Missing | 3.4 | 10.0 | — | 0.0 |
Clinical response was evaluated by the masked investigator as effective, ineffective and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.
| Percentage of participants | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia |
|---|---|---|---|---|
| Effective | 93.1 | 90.0 | — | 50.0 |
| Ineffective | 6.9 | 10.0 | — | 0.0 |
| Indeterminate | 0.0 | 0.0 | — | 50.0 |
Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.
| Percentage of participants | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia |
|---|---|---|---|---|
| Eradication | 93.1 | 100.0 | — | 100.0 |
| Persistence | 6.9 | 0.0 | — | 0.0 |
| Elimination (indeterminate) | 0.0 | 0.0 | — | 0.0 |
Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest.
| cm^2 | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI |
|---|---|---|
| Day 3/4 | -62.05 ± 96.89 | -173.93 ± 210.19 |
| Day 5 to 13 | -134.31 ± 153.3 | -317.66 ± 410.86 |
| End of treatment | -174.96 ± 283.05 | -280.69 ± 386.64 |
| Test of cure (n=28, 9) | -212.63 ± 369.43 | -314.18 ± 402.93 |
Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest. Reduction ratio (%) = 100 \* (the post baseline value - baseline value) / baseline value. Negative values represent reduction of lesion size compared to baseline.
| Percentage | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI |
|---|---|---|
| Day3/4 | -32.32 ± 40.50 | -61.46 ± 33.31 |
| Day 5 to 13 | -53.30 ± 41.66 | -94.61 ± 6.32 |
| End of Treatment | -67.69 ± 32.40 | -90.09 ± 26.38 |
| Test of Cure | -81.82 ± 23.99 | -99.09 ± 2.08 |
Collected over 25 days after the last study medication administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tedizolid Phosphate (Sivextro, BAY1192631) | — | 7/83 (8.4%) | 64/83 (77.1%) |
| Linezolid | — | 4/41 (9.8%) | 31/41 (75.6%) |
| Event | Tedizolid Phosphate (Sivextro, BAY1192631) | Linezolid |
|---|---|---|
| CellulitisInfections and infestations | 1/83 | 2/41 |
| Bone marrow failureBlood and lymphatic system disorders | 0/83 | 1/41 |
| SepsisInfections and infestations | 0/83 | 1/41 |
| Anal abscessInfections and infestations | 0/83 | 1/41 |
| Muscle abscessInfections and infestations | 0/83 | 1/41 |
| OsteomyelitisInfections and infestations | 2/83 | 0/41 |
| Gas gangreneInfections and infestations | 1/83 | 0/41 |
| Necrotising fasciitisInfections and infestations | 1/83 | 0/41 |
| PneumoniaInfections and infestations | 1/83 | 0/41 |
| SternitisInfections and infestations | 1/83 | 0/41 |
| Event | Tedizolid Phosphate (Sivextro, BAY1192631) | Linezolid |
|---|---|---|
| Dermatitis contactSkin and subcutaneous tissue disorders | 5/83 | 6/41 |
| ConstipationGastrointestinal disorders | 4/83 | 4/41 |
| DiarrhoeaGastrointestinal disorders | 4/83 | 4/41 |
| NauseaGastrointestinal disorders | 5/83 | 4/41 |
| VomitingGastrointestinal disorders | 4/83 | 4/41 |
| Injection site painGeneral disorders | 5/83 | 4/41 |
| Hepatic function abnormalHepatobiliary disorders | 3/83 | 3/41 |
| Alanine aminotransferase increasedInvestigations | 5/83 | 2/41 |
| AnaemiaBlood and lymphatic system disorders | 1/83 | 2/41 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/83 | 2/41 |
Participants who received treatment are analyzed for baseline characteristics.
| Age, Customized(Participants) | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia | Total |
|---|---|---|---|---|---|
| < 65 years | 31 | 20 | 3 | 0 | 54 |
| 65 - 75 years | 31 | 9 | 1 | 2 | 43 |
| > 75 years | 17 | 10 | 0 | 0 | 27 |
| Sex: Female, Male(Participants) | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia | Total |
|---|---|---|---|---|---|
| Female | 27 | 12 | 2 | 1 | 42 |
| Male | 52 | 27 | 2 | 1 | 82 |
| Body Mass Index (BMI)(kg/m^2) | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia | Total |
|---|---|---|---|---|---|
| Mean | 25.52 ± 4.70 | 25.72 ± 5.80 | 30.75 ± 11.19 | 22.35 ± 0.64 | 25.70 ± 5.34 |
| Lesion area(Participants) | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia | Total |
|---|---|---|---|---|---|
| <=75 cm^2 | 25 | 14 | — | — | 39 |
| >75 cm^2 | 54 | 25 | — | — | 79 |
| Primary diagnosis(Participants) | Tedizolid Phosphate (Sivextro, BAY1192631) - SSTI | Linezoid - SSTI | Tedizolid Phosphate (Sivextro, BAY1192631) - Bacteremia | Linezoid - Bacteremia | Total |
|---|---|---|---|---|---|
| Deep SSTI | 44 | 22 | 0 | 0 | 66 |
| Chronic pyoderma | 3 | 2 | 0 | 0 | 5 |
| Infection secondary to wound, burn, surgical wound | 15 | 10 | 0 | 0 | 25 |
| Infection secondary to ulcer | 17 | 5 | 0 | 0 | 22 |
| Bacteremia | 0 | 0 | 4 | 2 | 6 |
Ran from Nov 2013 to primary completion in Oct 2016, 35 months.
Results were first posted in Oct 2018, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate